Kynurenine pathway in Parkinson's disease—An update

Kaavya, 2020, Unraveling correlative roles of dopamine transporter (DAT) and parkin in Parkinson’s disease (PD)-a road to discovery?, Brain Res. Bull., 157, 169, 10.1016/j.brainresbull.2020.02.001 Mohana, 2020, Does retina play a role in Parkinson’s disease?, Acta Neurol. Belg., 120, 257, 10.1007/s13760-020-01274-w Dhivya, 2016, Screening of genetic mutations in early onset parkinsonism patients: a family based study in Tamil Nadu population, Int. J. Hum. Genet., 16, 158, 10.1080/09723757.2016.11886293 Schwarcz, 2012, Kynurenines in the mammalian brain: when physiology meets pathology, Nat. Rev. Neurosci., 13, 465, 10.1038/nrn3257 Platten, 2019, Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond, Nat. Rev. Drug Discov., 18, 379, 10.1038/s41573-019-0016-5 Cervenka, 2017, Kynurenines: tryptophan’s metabolites in exercise, inflammation, and mental health, Science, 357, eaaf9794, 10.1126/science.aaf9794 Munn, 2013, Indoleamine 2, 3 dioxygenase and metabolic control of immune responses, Trends Immunol., 34, 137, 10.1016/j.it.2012.10.001 Opitz, 2015, Dynamics of NAD-metabolism: everything but constant, Biochem. Soc. Trans., 43, 1127, 10.1042/BST20150133 Agudelo, 2018, Kynurenic acid and Gpr35 regulate adipose tissue energy homeostasis and inflammation, Cell Metab., 27, 378, 10.1016/j.cmet.2018.01.004 Zhang, 2016, Microbial metabolism of dietary components to bioactive metabolites: opportunities for new therapeutic interventions, Genome. Med., 8, 46, 10.1186/s13073-016-0296-x Kennedy, 2017, Kynurenine pathway metabolism and the microbiota-gut-brain axis, Neuropharmacol., 112, 399, 10.1016/j.neuropharm.2016.07.002 Breda, 2016, Tryptophan-2, 3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites, Proc. Natl. Acad. Sci. U. S. A., 113, 5435, 10.1073/pnas.1604453113 Erhardt, 2017, The kynurenine pathway in schizophrenia and bipolar disorder, Neuropharmacol., 112, 297, 10.1016/j.neuropharm.2016.05.020 Lim, 2017, Involvement of the kynurenine pathway in the pathogenesis of Parkinson’s disease, Prog. Neurobiol., 155, 76, 10.1016/j.pneurobio.2015.12.009 Török, 2015, The genetic link between Parkinson’s disease and the kynurenine pathway is still missing, Parkinsons Dis., 10.1155/2015/474135 Houser, 2017, The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis?, NPJ Parkinsons Dis., 3, 1, 10.1038/s41531-016-0002-0 Braidy, 2011, Changes in kynurenine pathway metabolism in the brain, liver and kidney of aged female Wistar rats, FEBS J., 278, 4425, 10.1111/j.1742-4658.2011.08366.x Braidy, 2019, Role of nicotinamide adenine dinucleotide and related precursors as therapeutic targets for age-related degenerative diseases: rationale, biochemistry, pharmacokinetics, and outcomes, Antioxid. Redox Signal., 30, 251, 10.1089/ars.2017.7269 Widner, 2002, Increased neopterin production and tryptophan degradation in advanced Parkinson's disease, J. Neural Transm., 109, 181, 10.1007/s007020200014 LeWitt, 2013, 3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis, Mov. Disord., 28, 1653, 10.1002/mds.25555 Lim, 2017, Involvement of the kynurenine pathway in the pathogenesis of Parkinson’s disease, Prog. Neurobiol., 155, 76, 10.1016/j.pneurobio.2015.12.009 Sas, 2018, Mitochondria, oxidative stress and the kynurenine system, with a focus on ageing and neuroprotection, Mol., 23, 191, 10.3390/molecules23010191 Guillemin, 2001, Kynurenine pathway metabolism in human astrocytes;a paradox for neuronal protection, J. Neurochem., 78, 842, 10.1046/j.1471-4159.2001.00498.x Chiarugi, 2001, Similarities and differences in the neuronal death processes activated by 3OH-kynurenine and quinolinic acid, J. Neurochem., 77, 1310, 10.1046/j.1471-4159.2001.00335.x Guidetti, 1999, 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum, Eur. J. Neurosci., 11, 3857, 10.1046/j.1460-9568.1999.00806.x Frick, 2004, Increasing production of homocysteine and neopterin and degradation of tryptophan with older age, Clin. Biochem., 37, 684, 10.1016/j.clinbiochem.2004.02.007 Pertovaara, 2006, Indoleamine 2, 3-dioxygenase activity in nonagenarians is markedly increased and predicts mortality, Mech. Ageing Dev., 127, 497, 10.1016/j.mad.2006.01.020 Van Der Goot, 2012, Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation, PNAS., 109, 14912, 10.1073/pnas.1203083109 La Cruz, 2012, Quinolinic acid, an endogenous molecule combining excitotoxicity, oxidative stress and other toxic mechanisms, IJTR., 5, S8158, 10.4137/IJTR.S8158 Coggan, 2009, Age and circadian influences on picolinic acid concentrations in human cerebrospinal fluid, J. Neurochem., 108, 1220, 10.1111/j.1471-4159.2009.05868.x Moroni, 1999, Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites, Eur. J. Pharmacol., 375, 87, 10.1016/S0014-2999(99)00196-X Kepplinger, 2005, Age-related increase of kynurenic acid in human cerebrospinal fluid–IgG and β2-microglobulin changes, Neurosignals., 14, 126, 10.1159/000086295 Gramsbergen, 1992, Age-related changes in kynurenic acid production in rat brain, Brain Res., 588, 1, 10.1016/0006-8993(92)91337-E Sorgdrager, 2019, Age-and disease-specific changes of the kynurenine pathway in Parkinson’s and Alzheimer’s disease, J. Neurochem., 151, 656, 10.1111/jnc.14843 Fang, 2017, NAD+ in aging: molecular mechanisms and translational implications, Trends Mol. Med., 23, 899, 10.1016/j.molmed.2017.08.001 Fang, 2014, Defective mitophagy in XPA via PARP-1 hyperactivation and NAD+/SIRT1 reduction, Cell J., 157, 882, 10.1016/j.cell.2014.03.026 Castro-Portuguez, 2020, Kynurenine pathway, NAD+ synthesis, and mitochondrial function: targeting tryptophan metabolism to promote longevity and healthspan, Exp. Gerontol., 132, 10.1016/j.exger.2020.110841 Bender, 1982, The preferred route of kynurenine metabolism in the rat, BBA–Gen Sub., 717, 56, 10.1016/0304-4165(82)90379-8 Grant, 2010, Kynurenine pathway metabolism is involved in the maintenance of the intracellular NAD+ concentration in human primary astrocytes, IJTR, 3, S4779, 10.4137/IJTR.S4779 Grant, 2003, Inhibition of indoleamine 2, 3-dioxygenase activity in IFN-γ stimulated astroglioma cells decreases intracellular NAD levels, Biochem. Pharmacol., 66, 1033, 10.1016/S0006-2952(03)00464-7 Grant, 2018, Indoleamine 2, 3-Dioxygenase activity increases NAD+ production in IFN-γ–stimulated human primary mononuclear cells, IJTR, 11, 10.1177/1178646917751636 Bellac, 2010, Inhibition of the kynurenine-NAD+ pathway leads to energy failure and exacerbates apoptosis in pneumococcal meningitis, J. Neuropathol. Exp. Neurol., 69, 1096, 10.1097/NEN.0b013e3181f7e7e9 Miranda, 1997, Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid, Neuroscience, 78, 967, 10.1016/S0306-4522(96)00655-0 Zinger, 2011, The involvement of neuroinflammation and kynurenine pathway in Parkinson's disease, Parkinsons Dis., 10.4061/2011/716859 Wu, 2002, Effect of systemic L-DOPA administration on extracellular kynurenate levels in the rat striatum, J. Neural Transm., 109, 239, 10.1007/s007020200020 Rassoulpour, 1998, Systemic d-amphetamine administration causes a reduction of kynurenic acid levels in rat brain, Brain Res., 802, 111, 10.1016/S0006-8993(98)00577-0 Kubesova, 2015, Biochemical, histopathological and morphological profiling of a rat model of early immune stimulation: relation to psychopathology, PLoS One, 10, 10.1371/journal.pone.0115439 Graham, 1990, Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism, Life Sci., 47, PL91, 10.1016/0024-3205(90)90376-3 Brotchie, 1991, Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate, J. Mov. Disord., 6, 133, 10.1002/mds.870060208 Knyihár-Csillik, 2006, Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra, Acta Neuropathol., 112, 127, 10.1007/s00401-006-0086-4 Lee, 2008, Kynurenic acid attenuates MPP+-induced dopaminergic neuronal cell death via a Bax-mediated mitochondrial pathway, Eur. J. Cell Biol., 87, 389, 10.1016/j.ejcb.2008.03.003 Silva-Adaya, 2011, Protective effect of L-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: implications of modulating kynurenate as a protective strategy, Neurotoxicol. Teratol., 33, 303, 10.1016/j.ntt.2010.10.002 Hartai, 2005, Kynurenine metabolism in plasma and in red blood cells in Parkinson’s disease, J. Neurol. Sci., 239, 31, 10.1016/j.jns.2005.07.006 Wu, 2007, Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain?, J. Neural Transm., 114, 33, 10.1007/s00702-006-0562-y Oxenkrug, 2017, Peripheral tryptophan-kynurenine metabolism associated with metabolic syndrome is different in Parkinson’s and Alzheimer’s diseases, Endocrinol, Diabetes Metab. J., 1 Beal, 1992, Kynurenic acid concentrations are reduced in Huntington’s disease cerebral cortex, J. Neurol. Sci., 108, 80, 10.1016/0022-510X(92)90191-M Ogawa, 1992, Kynurenine pathway abnormalities in Parkinson's disease, J. Neurol., 42, 1702 Havelund, 2017, Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia, J. Neurochem., 142, 756, 10.1111/jnc.14104 Guillemin, 2003, Quinolinic acid in the pathogenesis of Alzheimer’s disease, 167 Kepplinger, 2011, Stochastic resonance activity influences serum tryptophan metabolism in healthy human subjects, IJTR, 4, IJTR, 10.4137/IJTR.S7986 Ji, 2019, Study of metabolic disorders associated with BDE-47 exposure in Drosophila model by MS-based metabolomics, Ecotoxicol. Environ. Saf., 184, 10.1016/j.ecoenv.2019.109606 Kubicova, 2019, Coordination complex formation and redox properties of kynurenic and xanthurenic acid can affect brain tissue homeodynamics, Antioxidants, 8, 476, 10.3390/antiox8100476 Del Tredici, 2008, A not entirely benign procedure: progression of Parkinson’s disease, Acta Neuropathol., 115, 379, 10.1007/s00401-008-0355-5 Mulak, 2015, Brain-gut-microbiota axis in Parkinson's disease, World J. Gastroenterol., 21, 10609, 10.3748/wjg.v21.i37.10609 Böttner, 2012, Expression pattern and localization of alpha-synuclein in the human enteric nervous system, Neurobiol. Dis., 48, 474, 10.1016/j.nbd.2012.07.018 Forsyth, 2011, Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease, PLoS One, 6, e28032, 10.1371/journal.pone.0028032 Devos, 2013, Colonic inflammation in Parkinson's disease, Neurobiol. Dis., 50, 42, 10.1016/j.nbd.2012.09.007 Westfall, 2017, Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis, Cell. Mol. Life Sci., 74, 3769, 10.1007/s00018-017-2550-9 Dehhaghi, 2019, Microorganisms, tryptophan metabolism, and kynurenine pathway: a complex interconnected loop influencing human health status, IJTR., 12, 10.1177/1178646919852996 Gao, 2018, Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism, Front Cell Infect. Mi., 8, 13, 10.3389/fcimb.2018.00013 Vujkovic-Cvijin, 2013, Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism, Sci. Transl. Med., 5, 193ra91, 10.1126/scitranslmed.3006438 O’Farrell, 2017, Stress-related regulation of the kynurenine pathway: relevance to neuropsychiatric and degenerative disorders, Neuropharmacol., 112, 307, 10.1016/j.neuropharm.2015.12.004 Shoaie, 2015, Quantifying diet-induced metabolic changes of the human gut microbiome, Cell Metab., 22, 320, 10.1016/j.cmet.2015.07.001 El Aidy, 2014, Immune modulation of the brain-gut-microbe axis, Front. Microbiol., 5, 146, 10.3389/fmicb.2014.00146 Clarke, 2013, Targeting the microbiota to address diet-induced obesity: a time dependent challenge, PLoS One, 8, 10.1371/journal.pone.0065790 Wikoff, 2009, Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites, Proc. Natl. Acad. Sci. U. S. A., 106, 3698, 10.1073/pnas.0812874106 Tavassoly, 2018, Quinolinic acid amyloid-like fibrillar assemblies seed α-synuclein aggregation, J. Mol. Biol., 430, 3847, 10.1016/j.jmb.2018.08.002 Gheorghe, 2019, Focus on the essentials: tryptophan metabolism and the microbiome-gut-brain axis, Curr. Opin. Pharmacol., 48, 137, 10.1016/j.coph.2019.08.004 Anderson, 2016, Gut permeability and microbiota in Parkinson’s disease: role of depression, tryptophan catabolites, oxidative and nitrosative stress and melatonergic pathways, Curr. Pharm. Des., 22, 6142, 10.2174/1381612822666160906161513 Boros, 2018, Genetic alterations affecting the genes encoding the enzymes of the kynurenine pathway and their association with human diseases, Mutat. Res. Rev. Mutat., 776, 32, 10.1016/j.mrrev.2018.03.001 Ekelund, 2001, Chromosome 1 loci in finnish schizophrenia families, Hum. Mol. Genet., 10, 1611, 10.1093/hmg/10.15.1611 Blackwood, 2001, Schizophrenia and affective disorders—cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family, Am. J. Hum. Genet., 69, 428, 10.1086/321969 Gurling, 2001, Genome-wide genetic linkage analysis confirms the presence of susceptibility loci for schizophrenia, on chromosomes 1q32. 2, 5q33. 2, and 8p21–22 and provides support for linkage to schizophrenia, on chromosomes 11q23. 3–24 and 20q12. 1–11.23, Am. J. Hum. Genet., 68, 661, 10.1086/318788 Thirtamara-Rajamani, 2017, Is the enzyme ACMSD a novel therapeutic target in Parkinson’s disease?, Parkinson’s Dis., 7, 577, 10.3233/JPD-171240 Wang, 2019, Association of three candidate genetic variants in ACMSD/TMEM163, GPNMB and BCKDK/STX1B with sporadic Parkinson’s disease in Han Chinese, Neurosci. Lett., 703, 45, 10.1016/j.neulet.2019.03.019 Chang, 2019, Polymorphisms of ACMSD-TMEM163, MCCC1, and BCKDK-STX1B are not associated with Parkinson’s disease in Taiwan, Parkinson’s Dis., 10.1155/2019/3489638 Lill, 2012, Comprehensive research synopsis and systematic meta-analyses in Parkinson’s disease genetics: the PDGene database, PLoS Genet., 8, 10.1371/journal.pgen.1002548 Sharma, 2012, Large-scale replication and heterogeneity in Parkinson disease genetic loci, Neurology., 79, 659, 10.1212/WNL.0b013e318264e353 Pihlstrøm, 2013, Supportive evidence for 11 loci from genome-wide association studies in Parkinson's disease, Neurobiol. Aging, 34, 1708, 10.1016/j.neurobiolaging.2012.10.019 Bandrés-Ciga, 2016, Genome-wide assessment of Parkinson’s disease in a southern Spanish population, Neurobiol. Aging, 45, 213, 10.1016/j.neurobiolaging.2016.06.001 Nalls, 2014, Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease, Nat. Genet., 46, 989, 10.1038/ng.3043 Chang, 2017, A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci, Nat. Genet., 49, 1511, 10.1038/ng.3955 Martí-Massó, 2013, The ACMSD gene, involved in tryptophan metabolism, is mutated in a family with cortical myoclonus, epilepsy, and parkinsonism, J. Mol. Med., 91, 1399, 10.1007/s00109-013-1075-4 Vilas, 2017, A novel p. Glu298Lys mutation in the ACMSD gene in sporadic Parkinson’s disease, J. Parkinsons Dis., 7, 459, 10.3233/JPD-171146 Chahine, 2014, Blood-based biomarkers for Parkinson’s disease, Parkinsonism Relat. Disord., 20, S99, 10.1016/S1353-8020(13)70025-7 Burgos, 2014, Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer's and Parkinson's diseases correlate with disease status and features of pathology, PLoS One, 9, 10.1371/journal.pone.0094839 Luan, 2015, LC–MS-based urinary metabolite signatures in idiopathic Parkinson’s disease, J. Proteome Res., 14, 467, 10.1021/pr500807t Luan, 2015, Comprehensive urinary metabolomic profiling and identification of potential noninvasive marker for idiopathic Parkinson’s diseas, Sci. Rep., 5, 13888, 10.1038/srep13888 Iwaoka, 2020, Impaired metabolism of kynurenine and its metabolites in CSF of parkinson’s disease, Neurosci. Lett., 714, 10.1016/j.neulet.2019.134576 K.H. Chang, M.L. Cheng, H.Y. Tang, C.Y. Huang, Y.R. Wu, C.M. Chen, Alternations of metabolic profile and kynurenine metabolism in the plasma of Parkinson's disease, Mol. Neurobiol. 55 (2018) 6319–2638. doi:https://doi.org/10.1007/s12035-017-0845-3. Ravikumar, 2000, Tryptophan and tyrosine catabolic pattern in neuropsychiatric disorders, Neurol. India, 48, 231 Nemeth, 2006, Kynurenines, Parkinson’s disease and other neurodegenerative disorders: preclinical and clinical studies, J. Neurol., 285 Stachowski, 2012, Regulation of quinolinic acid neosynthesis in mouse, rat and human brain by iron and iron chelators in vitro, J. Neural Transm., 119, 123, 10.1007/s00702-011-0694-6 Malherbe, 1994, Molecular cloning and functional expression of human 3-hydroxyanthranilic-acid dioxygenase, J. Biol. Chem., 269, 13792, 10.1016/S0021-9258(17)36717-0 Natalini, 1995, Synthesis and activity of enantiopure (S)(m-nitrobenzoyl) alanine, potent kynurenine-3-hydroxylase inhibitor, Bioorg. Med. Chem. Lett., 5, 1451, 10.1016/0960-894X(95)00255-R Fukuyama, 2014, Zonisamide regulates basal ganglia transmission via astroglial kynurenine pathway, Neuropharmacol., 76, 137, 10.1016/j.neuropharm.2013.08.002 Stone, 2012, Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection, FEBS J., 279, 1386, 10.1111/j.1742-4658.2012.08487.x Jackson, 1995, Synthesis and biological activity of a series of 4-aryl substituted benz [b] azepines: antagonists at the strychnine-insensitive glycine site, Bioorg. Med. Chem. Lett., 5, 3097, 10.1016/0960-894X(95)00544-0 Wu, 1997, Enzyme-catalyzed production of the neuroprotective NMDA receptor antagonist 7-chlorokynurenic acid in the rat brain in vivo, Eur. J. Pharmacol., 319, 13, 10.1016/S0014-2999(96)00829-1 Wu, 2000, Systemic administration of 4-chlorokynurenine prevents quinolinate neurotoxicity in the rat hippocampus, Eur. J. Pharmacol., 390, 267, 10.1016/S0014-2999(00)00024-8 Lee, 2001, Excitotoxic injury stimulates pro-drug-induced 7-chlorokynurenate formation in the rat striatum in vivo, Neurosci. Lett., 304, 185, 10.1016/S0304-3940(01)01791-8 Battaglia, 2000, Systemically administered D-glucose conjugates of 7-chlorokynurenic acid are centrally available and exert anticonvulsant activity in rodents, Brain Res., 860, 149, 10.1016/S0006-8993(00)01962-4 Widnell, 2005, Pathophysiology of motor fluctuations in Parkinson’s disease, J Mov. Disord., 20, S17, 10.1002/mds.20459 Zádori, 2012, Kynurenines in Parkinson’s disease: therapeutic perspectives, J. Neural Transm., 119, 275, 10.1007/s00702-011-0697-3 Acuña-Castroviejo, 2011, Protective effects of synthetic kynurenines on 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced parkinsonism in mice, Brain Res. Bull., 85, 133, 10.1016/j.brainresbull.2011.03.008 Guidetti, 2000, In situ produced 7-chlorokynurenate provides protection against quinolinate-and malonate-induced neurotoxicity in the rat striatum, Exp. Neurol., 163, 123, 10.1006/exnr.1999.7284 Sas, 2007, Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders, J. Neurol. Sci., 257, 221, 10.1016/j.jns.2007.01.033 Perez-De La Cruz, 2007, Integrative hypothesis for Huntington’s disease: a brief review of experimental evidence, Physiol. Res., 56, 513, 10.33549/physiolres.931049 Grégoire, 2008, Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys, Behav. Brain Res., 186, 161, 10.1016/j.bbr.2007.08.007 Ouattara, 2009, Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias, J. Mol. Neurosci., 38, 128, 10.1007/s12031-008-9137-8 Samadi, 2005, Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys, J. Mov. Disord., 20, 792, 10.1002/mds.20596